Longevity & AgingThree IgA Nephropathy Drugs Cut Urinary Protein in Phase III Trials
IgA nephropathy treatments reduced protein leaking into urine in three ongoing clinical trials, offering encouraging evidence for adults with this immune-driven kidney disease. Povetacicept lowered urinary protein by 52.0%, ravulizumab by 46.6%, and sefaxersen by 46.9%, while placebo groups improved much less. These results were measured after roughly eight to nine months. Povetacicept also reduced an abnormal antibody linked to the disease and helped more patients clear blood from their urine. However, lower urinary protein does not yet prove that these drugs prevent kidney failure or preserve kidney function over time. The findings support further development and specialist discussions, not treatment changes based on headlines. The supplied article is incomplete, and longer-term kidney function results and detailed safety information remain essential.
